UPC CFI 147/2024
May 13, 2024·EP2493466 · NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- StatusCase Closed (No infringement)ActionInfringementCategoryMain infringement action
- Parties
- Claimants
- Sanofi Mature IPOperating co.
- Sanofi Winthrop IndustrieOperating co.
- Sanofi-Aventis FranceOperating co.
- Sanofi-Aventis GmbHOperating co.
- Sanofi BelgiumOperating co.
- Sanofi-Aventis Deutschland GmbHOperating co.
- Sanofi S.r.l.Operating co.
- Sanofi B.V.Operating co.
- Sanofi - Produtos Farmaceuticos LdaOperating co.
- Sanofi ABOperating co.
- Sanofi A/SOperating co.
Representatives- Agathe Michel-De Cazotte-Carpmaels & Ransford
- Frédéric Chevallier-McDermott Will & Schulte
Respondents- Reddy Pharma SASOperating co.
- betapharm Arzneimittel GmbHOperating co.
- Dr Reddy's SrlOperating co.
Representatives- Christian Meyer-Maiwald
- Konstantin Schallmoser-Bonabry
- Anja Lunze-PENTARC Rechtsanwälte PartGmbB
- Daniel Hoppe-Bonabry
- Division
- Munich LD
- Technology
- ChemistryPharmaceuticals
- Language
- English
- First decided
- Dec 12, 2025
- EPO Opposition
- Glenmark Pharmaceuticals Europe Ltd2021-03-10
- Accord Healthcare LtdAdmissible2021-03-10
- Teva Pharmaceutical Industries Ltd.Admissible2021-03-10
- EVER Valinject GmbHWithdrawn2021-03-12
- Zentiva k.s.Admissible2021-03-12
- medac Gesellschaft für klinische Spezialpräparate mbHWithdrawn2021-03-22
- Fresenius Kabi Deutschland GmbHAdmissible2021-03-23
- Dr. Reddy's Laboratories Ltd.Admissible2021-03-31
- Betapharm Arzneimittel GmbHAdmissible2021-03-31
- Generics (U.K.) LimitedAdmissible2021-06-08
- Vossius & Partner Patentanwälte Rechtsanwälte mbBAdmissible2021-12-03
- STADA Arzneimittel AGAdmissible2021-12-09
- Maiwald GmbHAdmissible2021-12-10
- Accord Healthcare S.L.U.2024-08-30
| Infringement found | Median days to first decision | |
|---|---|---|
| All UPC | 53% (62/117) | 124 |
| Munich LD | Locked | Locked |
| Judge Matthias Zigann | Locked | Locked |
| Judge Alima Zana | Locked | Locked |
| Judge Tobias Pichlmaier | Locked | Locked |
| Judge Carola Wagner | Locked | Locked |
At the UPC: Sanofi Group (33 cases)·Reddy Pharma SAS (8 cases)
This dispute contains 7 other proceedings
UPC CoA 23/2026·UPC CoA 26/2026·UPC CFI 92/2026·UPC CFI 374/2024·CC 49716/2024 and 2 more
10 other defendants litigating the same or a related patent
UPC CoA 22/2026·UPC CoA 24/2026·UPC CoA 25/2026·UPC CoA 27/2026·UPC CFI 496/2024 and 5 more
- 2025-12-12Infringement ActionPublic
Summary: The Munich Local Division issued a rectification order under Rule 353 RoP correcting factual errors in a prior decision in the Sanofi v. Stada/Dr Reddy/Zentiva proceedings, including corrections regarding marketing authorisation holders and expert witness attribution.
Show the legal issues (1)
- Rectification of decisions Rule 353 RoP
- 2025-12-12Infringement ActionPublic
Summary: The Munich Local Division found patent EP 2 493 466 (relating to cabazitaxel pharmaceutical formulations) invalid for lack of inventive step in infringement proceedings brought by Sanofi against STADA, Dr. Reddy's and Zentiva entities, dismissing the infringement claims.
Show the legal issues (4)
- Inventive step (cabazitaxel formulation)
- Infringement
- Pharmaceutical patent
- Counterclaim for revocation
| Document title | Date | Public |
|---|---|---|
| Note | 2026-04-15 | Not public |
| Note | 2026-03-11 | Not public |
| Decision | 2026-02-13 | Not public |
| Final Order | 2026-02-13 | Public |
| Note | 2026-02-06 | Not public |
| Receipt | 2026-02-04 | Not public |
| Cover sheet | 2026-02-04 | Not public |
| Application document Claimant | 2026-02-04 | Not public |
| Receipt | 2026-01-12 | Not public |
| Cover sheet | 2026-01-12 | Not public |